Coppock, Matthew B.; Warner, Candice R.; Dorsey, Brandi; Orlicki, Joshua A.; Sarkes, Deborah A.; Lai, Bert T.; Pitram, Suresh M.; Rohde, Rosemary D.; Malette, Jacquie; Wilson, Jere A.; Kearney, Paul; Fang, Kenneth C.; Law, Scott M.; Candelario, Sherri L.; Farrow, Blake; Finch, Amethist S.; Agnew, Heather D.; Heath, James R.; Stratis-Cullum, Dimitra N. published an article in 2017, the title of the article was Protein Catalyzed Capture Agents with Tailored Performance for In Vitro and In Vivo Applications.Reference of tert-Butyl trichloroacetimidate And the article contains the following content:
We report on peptide-based ligands matured through the Protein Catalyzed Capture (PCC) agent method to tailor mol. binders for in vitro sensing/diagnostics and in vivo pharmacokinetics parameters. A Vascular Endothelial Growth Factor (VEGF) binding peptide and a peptide against the Protective Antigen (PA) protein of Bacillus anthracis discovered through phage and bacterial display panning technologies, resp., were modified with click handles and subjected to iterative in situ click chem. screens using synthetic peptide libraries. Each azide-alkyne cycloaddition iteration, promoted by the resp. target proteins, yielded improvements in metrics for the application of interest. The anti-VEGF PCC was explored as a stable in vivo imaging probe. It exhibited excellent stability against proteases and a mean elimination in vivo half-life (T1/2) of 36 min. I.p. injection of the reagent results in slow clearance from the peritoneal cavity and kidney retention at extended times, while i.v. injection translates to rapid renal clearance. The ligand competed with the com. antibody for binding to VEGF in vivo. The anti-PA ligand was developed for detection assays that perform in demanding phys. environments. The matured anti-PA PCC exhibited no solution aggregation, no fragmentation when heated to 100 oC, and a > 81% binding activity for PA after heating at 90°C for 1 h. We discuss the potential of the PCC agent screening process for the discovery and enrichment of next generation antibody alternatives. The experimental process involved the reaction of tert-Butyl trichloroacetimidate(cas: 98946-18-0).Reference of tert-Butyl trichloroacetimidate
The Article related to vegf binding peptide pet imaging agent pharmacokinetics, biological stability, peptide, protective antigen, protein catalyzed capture agent, synthetic antibody, thermal stability, vascular endothelial growth factor and other aspects.Reference of tert-Butyl trichloroacetimidate
Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics